

Find It @



Free Full Text from Publisher



Look Up Full Text

Full Text Options



Save to EndNote online

Add to Marked List

1 of 1

In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris

By: Hajizadeh, R (Hajizadeh, Reza)^[1]; Ghaffari, S (Ghaffari, Samad)^[1]; Ziaee, M (Ziaee, Mojtaba)^[2]; Shokouhi, B (Shokouhi, Behrooz)^[1]; Separham, A (Separham, Ahmad)^[1]; Sarbakhsh, P (Sarbakhsh, Parvin)^[1]

JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH

Volume: 9 Issue: 4 Pages: 191-195

DOI: 10.15171/jcvtr.2017.33

Published: 2017

Abstract

Introduction: Clopidogrel is a potent platelet activation and aggregation inhibitor that prevents thrombosis in coronary artery diseases (CADs). In comparison to locally produced generic one (Osvix (R)), original brand of clopidogrel (Plavix (R)) is expensive. This study was designed to evaluate the effectiveness and uniformity of Osvix (R) versus Plavix (R) in patients with percutaneous coronary intervention (PCI) by means of platelet aggregation indexes.

Methods: This randomized, double blind clinical study was conducted at Shahid Madani heart hospital, Tabriz, Iran, and 129 patients with previous PCI were enrolled in two independent treatment groups. All patients participated in this study were on dual antiplatelet therapy at least for 30 days. ASA 80 mg/d and clopidogrel 75 mg/d and a stat dose of 300 mg of clopidogrel before PCI were administered for all patients. To evaluate the anti-platelet activity, blood samples were taken from the patients and platelet aggregation test was performed.

Results: The total study population represents a group of 129 patients (99 men and 30 women) with mean age of 57.7 +/- 9.7 years with stable angina pectoris. The baseline characteristics and laboratory findings of two groups (except mean platelet volume [MPV]) were not different statistically. The mean platelets aggregation at 30th day was 13.7 +/- 7.0 in Plavix (R) group and 14.8 +/- 5.8 in Osvix (R) group (P value = 0.35).

Conclusion: This study showed that Osvix (R) as a generic form of clopidogrel was not significantly different from the original brand (Plavix) in terms of in vitro platelet inhibition.

Keywords

Author Keywords: Stable Angina; Clopidogrel; Generic; Brand; Platelet Aggregation

KeyWords Plus: CORONARY-ARTERY-DISEASE; HEART-DISEASE; MYOCARDIAL-INFARCTION; GLOBAL BURDEN; ASPIRIN; EVENTS; THERAPY; DRUGS; LABEL; OPCES

Author Information

Reprint Address: Ziaee, M (reprint author)

+ ACECR, Med Plant Res Ctr, Inst Med Plants, Karaj, Iran.

Addresses:

+ [1] Tabriz Univ Med Sci, Cardiovasc Res Ctr, Tabriz, Iran

Citation Network

In Web of Science Core Collection

0

Times Cited



Create Citation Alert

27

Cited References

[View Related Records](#)

Use in Web of Science

Web of Science Usage Count

0

Last 180 Days

0

Since 2013

[Learn more](#)

This record is from:
Web of Science Core Collection
- Emerging Sources Citation Index

Suggest a correction

If you would like to improve the quality of the data in this record, please [suggest a correction](#).

+ [2] ACECR, Med Plant Res Ctr, Inst Med Plants, Karaj, Iran

E-mail Addresses: Ziaee@imp.ac.ir

Funding

Funding Agency	Grant Number
Cardiovascular Research Center of Tabriz University of Medical Sciences, Tabriz, Iran	

[View funding text](#)

Publisher

TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICES, DANESHGHAH ST, TABRIZ, REPUBLIC ISLAMIC 51664-14766, IRAN

Categories / Classification

Research Areas: Cardiovascular System & Cardiology

Web of Science Categories: Cardiac & Cardiovascular Systems

Document Information

Document Type: Article

Language: English

Accession Number: WOS:000423915300002

PubMed ID: [29391931](#)

ISSN: 2008-5117

eISSN: 2008-6830

Other Information

IDS Number: FU5TG

Cited References in Web of Science Core Collection: 27

Times Cited in Web of Science Core Collection: 0